Phase 2 · NCT05951192

TRANSCEND-T2D

CompletedUnverified

Registry record

Trial details

Trial
TRANSCEND-T2D
ClinicalTrials.gov ID
NCT05951192
Indication
Type 2 diabetes glycaemic control
Phase
Phase 2
Study type
Not reported
Sponsor
Eli Lilly and Company
Enrolment
540
Status
Completed
Interventions
Not reported
Comparator
Not reported
Eligible ages
Not reported
Locations
Not reported
Study start
Not reported
Primary completion
31 Mar 2026
Study completion
Not reported

Verification

Last verified
Data pending
Source
Data pending
Registry last updated
Data pending